TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11095450

Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH) at a mean dose of 6.7 microg/kg x day (1.6 IU/day)
Number of subjects: 11
Study: 9274583

Group type: EXPERIMENTAL
Intervention: Home-based psychosocial nursing intervention (n = 692)
Number of subjects: 1376

Group type: COMPARATOR
Intervention: Usual care (n = 684)
Number of subjects: 1376
Study: 8036599

Group type: EXPERIMENTAL
Intervention: Prospidin (total dose 3.0‐9.8 g)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Azathioprine
Number of subjects: 40
Study: 3548485

Group type: EXPERIMENTAL
Intervention: 5% lidocaine in 7.5% glucose (LG)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 5% meperidine in water
Number of subjects: 40
Study: 29132073

Group type: EXPERIMENTAL
Intervention: Text-message-based maintenance intervention with standardized messages targeting emotion regulation
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Text-message-based maintenance intervention with individualized messages
Number of subjects: 226

Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 226
Study: 27425565

Group type: EXPERIMENTAL
Intervention: Strong Minds program (acceptance and commitment therapy combined with positive psychology)
Number of subjects: 267
Study: 23895414

Group type: EXPERIMENTAL
Intervention: LED group (treadmill training with phototherapy)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Exercise group (treadmill training only)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sedentary group (no training or phototherapy)
Number of subjects: 30
Study: 22732747

Group type: EXPERIMENTAL
Intervention: 3-step critical pathway
Number of subjects: 401

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 401
Study: 20557379

Group type: EXPERIMENTAL
Intervention: Falls prevention programme interventions based on assessment findings
Number of subjects: 712

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 712
Study: 18696749

Group type: EXPERIMENTAL
Intervention: Cladistic methods based on Templeton's algorithm (TA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cladistic methods based on Durrant et al.'s hierarchical clustering
Number of subjects: 0
Study: 16180634

Group type: EXPERIMENTAL
Intervention: Zinc-oxide eugenol
Number of subjects: 11
Study: 12765670

Group type: EXPERIMENTAL
Intervention: High-protein disease-specific enteral formula
Number of subjects: 50

Group type: COMPARATOR
Intervention: High-protein enteral formula (control)
Number of subjects: 50
Study: 9873844

Group type: EXPERIMENTAL
Intervention: BPL 8Y factor VIII concentrate
Number of subjects: 33
Study: 7847302

Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg q.i.d.)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 2688884

Group type: EXPERIMENTAL
Intervention: Intravenous thrombolytic therapy
Number of subjects: 0
Study: 30755573

Group type: EXPERIMENTAL
Intervention: Palonosetron (Group A, n=34)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Ondansetron (Group B, n=34)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Granisetron (Group C, n=34)
Number of subjects: 102
Study: 28965164

Group type: EXPERIMENTAL
Intervention: ACV preservation (group 1) - one rectus muscle operated (group A)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: ACV preservation (group 1) - two rectus muscles operated (group B)
Number of subjects: 73

Group type: COMPARATOR
Intervention: No ACV preservation (group 2) - one rectus muscle operated (group C)
Number of subjects: 73

Group type: COMPARATOR
Intervention: No ACV preservation (group 2) - two rectus muscles operated (group D)
Number of subjects: 73
Study: 25345750

Group type: EXPERIMENTAL
Intervention: Xalatan
Number of subjects: 19

Group type: COMPARATOR
Intervention: Glautan
Number of subjects: 19
Study: 23955106

Group type: EXPERIMENTAL
Intervention: d-chlorpheniramine 4 mg
Number of subjects: 27

Group type: COMPARATOR
Intervention: d-chlorpheniramine 2 mg
Number of subjects: 27

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 27
Study: 21422197

Group type: EXPERIMENTAL
Intervention: Leptin administration (replacement doses)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Leptin administration (pharmacological doses)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Leptin replacement in women with hypothalamic amenorrhea
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo administration in women with hypothalamic amenorrhea
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Acute starvation
Number of subjects: 52
Study: 19411525

Group type: EXPERIMENTAL
Intervention: Flumazenil (0.2 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 17275695

Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin administration (0.6 mg)
Number of subjects: 45
Study: 15851825

Group type: EXPERIMENTAL
Intervention: Multicomponent exercise program (3 sessions per week for 9 weeks)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 42
Study: 11514686

Group type: EXPERIMENTAL
Intervention: 200 microg inhaled salbutamol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 800 microg inhaled salbutamol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 9764337

Group type: EXPERIMENTAL
Intervention: Deferoxamine (100 mg/kg/d infused for a total of 72 h)
Number of subjects: 352

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Deferoxamine
Number of subjects: 352
Study: 7512124

Group type: EXPERIMENTAL
Intervention: Growth factors (GFs) including G-CSF (7.5 micrograms/kg/d) and GM-CSF (2.5 micrograms/kg/d) administered as a 2-hour intravenous infusion twice per day until neutrophil count > 1,500/microL
Number of subjects: 37

Group type: COMPARATOR
Intervention: No growth factors (Control)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Growth factors (GFs)
Number of subjects: 37
Study: 3948703

Group type: EXPERIMENTAL
Intervention: Indoramin (0.2‐0.4 mg/kg bodyweight)
Number of subjects: 12
Study: 29696404

Group type: EXPERIMENTAL
Intervention: Mother-to-child transmission (MTCT) of HIV prevention program (Option A - infant prophylaxis)
Number of subjects: 0
Study: 27584088

Group type: EXPERIMENTAL
Intervention: Home-based follow-up
Number of subjects: 1246

Group type: EXPERIMENTAL
Intervention: Telephone-based follow-up
Number of subjects: 1246

Group type: COMPARATOR
Intervention: Passive or needs-based follow-up
Number of subjects: 1246

Group type: EXPERIMENTAL
Intervention: Active follow-up (home-based + telephone-based)
Number of subjects: 1246

Group type: COMPARATOR
Intervention: Active vs Passive follow-up
Number of subjects: 1246

Group type: EXPERIMENTAL
Intervention: Telephone-based vs Home-based follow-up
Number of subjects: 1246
Study: 24718568

Group type: EXPERIMENTAL
Intervention: Monitoring arm (platelet function monitoring with drug adjustment)
Number of subjects: 2440

Group type: COMPARATOR
Intervention: Conventional arm (no monitoring, no drug or dose changes)
Number of subjects: 2440

Group type: EXPERIMENTAL
Intervention: Monitoring arm
Number of subjects: 2440

Group type: COMPARATOR
Intervention: Conventional arm
Number of subjects: 2440
Study: 23316296

Group type: EXPERIMENTAL
Intervention: Higher resting heart rate
Number of subjects: 11140
Study: 20196974

Group type: EXPERIMENTAL
Intervention: 6.6 g marine n‐3 PUFA/day
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 2.0 g marine n‐3 PUFA/day
Number of subjects: 60

Group type: COMPARATOR
Intervention: 6.6 g olive oil (control)
Number of subjects: 60
Study: 18779540

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa plus aerobic exercise training (DEX; n = 26)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Darbepoetin alfa alone (DAL; n = 29)
Number of subjects: 55
Study: 18044706

Group type: EXPERIMENTAL
Intervention: STN-DBS and levodopa (ON(MED)/ON(STIM))
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: STN-DBS only (OFF(MED)/ON(STIM))
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: levodopa only (ON(MED)/OFF(STIM))
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: without STN-DBS/levodopa (OFF(MED)/OFF(STIM))
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (14 volunteers)
Number of subjects: 8
Study: 15179022

Group type: EXPERIMENTAL
Intervention: Escitalopram (10-20 mg)
Number of subjects: 293

Group type: COMPARATOR
Intervention: Venlafaxine XR (75-150 mg)
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 293

Group type: COMPARATOR
Intervention: Venlafaxine XR
Number of subjects: 293
Study: 12026269

Group type: EXPERIMENTAL
Intervention: Classroom intervention
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Parent-classroom intervention
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3
Study: 9302488

Group type: EXPERIMENTAL
Intervention: Creatine (Cr) supplementation (5 g creatine plus 1 g glucose X 5 doses daily for 7 days)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (Pl) treatment (6 g glucose X 5 doses daily for 7 days)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Creatine (Cr) supplementation
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (Pl) treatment
Number of subjects: 9
Study: 8171738

Group type: EXPERIMENTAL
Intervention: IL-2 subcutaneous therapy (3 million IU twice/daily for 5 days/week for 6 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: IL-2 plus interferon-alpha (5 million U/m2 subcutaneously thrice weekly)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: IL-2 subcutaneous therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: IL-2 plus interferon-alpha
Number of subjects: 30
Study: 3534842

Group type: EXPERIMENTAL
Intervention: 25-50 mg hydrochlorothiazide and 50-100 mg of triamterene daily (active treatment group)
Number of subjects: 507

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: Active treatment group
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 507
Study: 31177888

Group type: EXPERIMENTAL
Intervention: 24-h urine protein excretion
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Instant and 24-h urine protein/creatinine (P/Cr) and albumin/creatinine (A/Cr) ratios
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: 24-h urine P/Cr ratio
Number of subjects: 118
Study: 28099502

Group type: EXPERIMENTAL
Intervention: Lenalidomide (21 days of a 28 days cycle)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Gemcitabine (standard regimen)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Lenalidomide + Gemcitabine
Number of subjects: 21
Study: 25885913

Group type: EXPERIMENTAL
Intervention: Pedometer-driven walking programme
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Back care advice and education followed by pedometer-driven walking programme
Number of subjects: 200

Group type: COMPARATOR
Intervention: Back care advice and education (Control)
Number of subjects: 200
Study: 24004961

Group type: EXPERIMENTAL
Intervention: Ceramic inlay/onlay
Number of subjects: 400

Group type: COMPARATOR
Intervention: Composite inlay/onlay
Number of subjects: 400
Study: 22287304

Group type: EXPERIMENTAL
Intervention: Drug-eluting stent
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control stent
Number of subjects: 43
Study: 18719908

Group type: EXPERIMENTAL
Intervention: Off-site PCI (n = 68)
Number of subjects: 128

Group type: COMPARATOR
Intervention: On-site PCI (n = 60)
Number of subjects: 128
Study: 16420567

Group type: COMPARATOR
Intervention: Standard dosage of rFVIIa (90 microg kg(‐1), repeated every 3 h)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High dosage of rFVIIa (270 microg kg(‐1), single dose)
Number of subjects: 20
Study: 15520310

Group type: COMPARATOR
Intervention: Circumferential pulmonary vein ablation (CPVA) alone (group 1)
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Modified circumferential pulmonary vein ablation (group 2)
Number of subjects: 560
Study: 11751698

Group type: EXPERIMENTAL
Intervention: Angiotensin II infusion (0.5 and 3 ng/kg per minute)
Number of subjects: 121
Study: 9015016

Group type: EXPERIMENTAL
Intervention: U removal technique
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard technique
Number of subjects: 24
Study: 8392297

Group type: EXPERIMENTAL
Intervention: Adinazolam (slow-release form)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 3080871

Group type: EXPERIMENTAL
Intervention: Oral rehydration therapy (60 mEq/L sodium, 20 mEq/L potassium, 50 mEq/L chloride, 30 mEq/L citrate, 20 g/L glucose, 5 g/L fructose)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Oral rehydration therapy
Number of subjects: 29

Group type: COMPARATOR
Intervention: Intravenous rehydration therapy
Number of subjects: 29
Study: 30299024

Group type: EXPERIMENTAL
Intervention: Dance therapy (DT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-treated group (Control)
Number of subjects: 0
Study: 29695208

Group type: EXPERIMENTAL
Intervention: Modified GnRH agonist protocol (group A)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Mild stimulation protocol (group B)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Antagonist protocol (group C)
Number of subjects: 116

Group type: COMPARATOR
Intervention: All groups (A, B, C)
Number of subjects: 116
Study: 27955644

Group type: EXPERIMENTAL
Intervention: Stypro hemostatic sponge
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Collagen hemostatic sponge
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gelatin sponge
Number of subjects: 0
Study: 24814202

Group type: EXPERIMENTAL
Intervention: Propofol (PRO)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Dexmedetomidine (DEX)
Number of subjects: 95
Study: 22349668

Group type: EXPERIMENTAL
Intervention: Vitamin D(3) oral drops
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo oral drops
Number of subjects: 80
Study: 19703572

Group type: EXPERIMENTAL
Intervention: Xenon (glutamate receptor antagonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18351483

Group type: EXPERIMENTAL
Intervention: Social comfort with EXPLORE participants
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Trust of other EXPLORE participants
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Feeling detached from EXPLORE
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Perception that EXPLORE participants are cunning
Number of subjects: 271
Study: 16151341

Group type: EXPERIMENTAL
Intervention: 16-channel paired stimulation with 5000 pps per channel
Number of subjects: 13

Group type: COMPARATOR
Intervention: 16-channel sequential stimulation with 2500 pps per channel
Number of subjects: 13

Group type: COMPARATOR
Intervention: 8-channel sequential stimulation with 5000 pps per channel
Number of subjects: 13
Study: 12030996

Group type: EXPERIMENTAL
Intervention: Enteral feeds
Number of subjects: 54

Group type: COMPARATOR
Intervention: Intravenous fluid
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 54
Study: 10098611

Group type: EXPERIMENTAL
Intervention: EEG analysis in patients with schizophrenia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 8533058

Group type: EXPERIMENTAL
Intervention: New antiepileptic drugs (vigabatrin, lamotrigine, gabapentin, oxcarbazepine, felbamate)
Number of subjects: 0
Study: 1975473

Group type: EXPERIMENTAL
Intervention: bucindolol
Number of subjects: 19

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 19
Study: 837099

Group type: EXPERIMENTAL
Intervention: Tear-off calendar
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Tablet identification card
Number of subjects: 46

Group type: COMPARATOR
Intervention: Standard instructions
Number of subjects: 46
Study: 31837105

Group type: EXPERIMENTAL
Intervention: Moral distress measured using the Moral Distress Scale‐Revised (MDS‐R)
Number of subjects: 612

Group type: EXPERIMENTAL
Intervention: High moral distress level
Number of subjects: 612
Study: 30845333

Group type: EXPERIMENTAL
Intervention: Vi-polysaccharide conjugate vaccine (Vi-TCV)
Number of subjects: 32500
Study: 28414267

Group type: EXPERIMENTAL
Intervention: Long duration low intensity ultrasound for active trapezius trigger points
Number of subjects: 0
Study: 26423195

Group type: EXPERIMENTAL
Intervention: Opt-out rapid HIV testing
Number of subjects: 83435

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 83435
Study: 23593139

Group type: EXPERIMENTAL
Intervention: Electroacupuncture at acupoint (treatment group)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Electroacupuncture at non-acupoint (control group)
Number of subjects: 100
Study: 21768545

Group type: EXPERIMENTAL
Intervention: Insulin-sensitizing strategy
Number of subjects: 2368
Study: 20110037

Group type: EXPERIMENTAL
Intervention: Test formulation of bicalutamide 50-mg tablets
Number of subjects: 34

Group type: COMPARATOR
Intervention: Reference formulation of bicalutamide 50-mg tablets
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 34
Study: 16919575

Group type: EXPERIMENTAL
Intervention: Stress gated SPECT regional wall motion abnormality
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Stress gated SPECT LVEF
Number of subjects: 27
Study: 17136995

Group type: EXPERIMENTAL
Intervention: Tiotropium, an inhaled anticholinergic, with once-daily dosing for four years.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified in the abstract.
Number of subjects: 0
Study: 11718031

Group type: EXPERIMENTAL
Intervention: Mifepristone 5 mg (Group A)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Mifepristone 10 mg (Group B)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Mifepristone 5 mg or 10 mg
Number of subjects: 39
Study: 9521944

Group type: EXPERIMENTAL
Intervention: Sexual abuse during childhood
Number of subjects: 1026

Group type: EXPERIMENTAL
Intervention: Incidents of physical abuse
Number of subjects: 1026

Group type: EXPERIMENTAL
Intervention: Major physical abuse or emotional abuse
Number of subjects: 1026
Study: 8296850

Group type: EXPERIMENTAL
Intervention: Intramuscular vitamin K1 (17 mothers)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo (16 mothers)
Number of subjects: 33
Study: 2574626

Group type: EXPERIMENTAL
Intervention: Terfenadine (60 mg) twice daily
Number of subjects: 66

Group type: COMPARATOR
Intervention: Terfenadine (60 mg) and phenylpropanolamine (50 mg) combination tablet twice daily
Number of subjects: 66
Study: 167673

Group type: EXPERIMENTAL
Intervention: ACTH
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31143019

Group type: EXPERIMENTAL
Intervention: Bhramari pranayama breathing exercise
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional treatment of chronic sinusitis
Number of subjects: 60
Study: 30104102

Group type: EXPERIMENTAL
Intervention: Gd+ areas with T2W hyperintensity (Gd+/T2high)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Gd+ areas with T2W isointensity (Gd+/T2iso)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Cell density
Number of subjects: 41
Study: 26180053

Group type: EXPERIMENTAL
Intervention: Real iTBS
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sham iTBS
Number of subjects: 18
Study: 24840766

Group type: EXPERIMENTAL
Intervention: Audiorecorded visits with caregivers discussing caregiving problems and coping strategies
Number of subjects: 4
Study: 23222963

Group type: EXPERIMENTAL
Intervention: Grape consumption (46 g of lyophilized grape powder daily for four weeks)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (identical macronutrient composition and caloric value as GRAPE)
Number of subjects: 24
Study: 20961828

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (IT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study: 17027139

Group type: EXPERIMENTAL
Intervention: Posterior polymer crowns with glass-fiber framework (group 1)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Posterior polymer crowns without glass-fiber framework (group 2)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional metal-ceramic crowns (control group)
Number of subjects: 80
Study: 16287792

Group type: EXPERIMENTAL
Intervention: Efavirenz
Number of subjects: 303

Group type: COMPARATOR
Intervention: Control (not receiving efavirenz)
Number of subjects: 303
Study: 12428180

Group type: EXPERIMENTAL
Intervention: Beer consumption (4 glasses for men, 3 glasses for women)
Number of subjects: 19

Group type: COMPARATOR
Intervention: No-alcohol beer (control)
Number of subjects: 19
Study: 10401939

Group type: EXPERIMENTAL
Intervention: 10 mg of metoclopramide
Number of subjects: 10

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 10
Study: 7734367

Group type: EXPERIMENTAL
Intervention: 2 mg cladribine/m2/d
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: 1 mg cladribine/m2/d
Number of subjects: 102

Group type: COMPARATOR
Intervention: Standard dose (3.4 mg/m2 or 0.085 mg/kg)
Number of subjects: 102
Study: 2193636

Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate (TU)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal fT levels (control group)
Number of subjects: 0
Study: 7398190

Group type: EXPERIMENTAL
Intervention: Diphenhydramine 50 mg/70 kg body weight (intravenously or orally)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 6342648

Group type: EXPERIMENTAL
Intervention: Topical PUVA with 2-h interval therapy (1% 8-methoxypsoralen followed by UV-A exposure 2 hours later)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Topical PUVA with non-interval therapy (1% 8-methoxypsoralen followed by UV-A exposure within 5 minutes)
Number of subjects: 15
Study: 31594891

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injection
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (saline) injection
Number of subjects: 100
Study: 30630792

Group type: EXPERIMENTAL
Intervention: Intradermal injection of tranexamic acid and glutathione
Number of subjects: 180

Group type: COMPARATOR
Intervention: Pure topical therapy of hydroquinone ointment
Number of subjects: 180
Study: 27245981

Group type: EXPERIMENTAL
Intervention: Lurasidone
Number of subjects: 144
Study: 24113563

Group type: EXPERIMENTAL
Intervention: Group psychoeducational intervention (PIP)
Number of subjects: 238

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 238
Study: 22334123

Group type: EXPERIMENTAL
Intervention: Intravenous nicotine (0.5 and 1.0 mg/70 kg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 100